Business Description
Replek AD
ISIN : MKREPL101013
Description
Replek AD is engaged in the development, design and production of generic medicines. The company develops drugs in different pharmaceutical therapeutic categories including anti-platelet, lipid-lowering, atypical antipsychotic, anti-infective, among others. It manufactures drugs in different forms including tablets, capsules, oral solutions, creams and ointments. Its product portfolio consists of Clopidogrel, Atorvastatin, Simvastatin, risperidone, Clarythromycin, Ciprofloxacin, Meloksikam, Risperidon, terazosin, among others. Replek also offers cannabis oil products, food supplements and cosmetics.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.21 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | 1.4 | |||||
| Interest Coverage | 68.12 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 3.89 | |||||
| Beneish M-Score | 20.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.4 | |||||
| 3-Year EBITDA Growth Rate | 25.4 | |||||
| 3-Year EPS without NRI Growth Rate | 47.2 | |||||
| 3-Year FCF Growth Rate | 45.7 | |||||
| 3-Year Book Growth Rate | 13.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 87.43 | |||||
| 9-Day RSI | 81.09 | |||||
| 14-Day RSI | 77.05 | |||||
| 6-1 Month Momentum % | 28.74 | |||||
| 12-1 Month Momentum % | 61.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.2 | |||||
| Quick Ratio | 0.48 | |||||
| Cash Ratio | 0.11 | |||||
| Days Inventory | 707.65 | |||||
| Days Sales Outstanding | 73.68 | |||||
| Days Payable | 290.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.82 | |||||
| 3-Year Dividend Growth Rate | -24.4 | |||||
| Forward Dividend Yield % | 1.82 | |||||
| 5-Year Yield-on-Cost % | 1.82 | |||||
| Shareholder Yield % | 1.11 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.08 | |||||
| Operating Margin % | 23.57 | |||||
| Net Margin % | 19.46 | |||||
| FCF Margin % | 21.95 | |||||
| ROE % | 9.84 | |||||
| ROA % | 7.04 | |||||
| ROIC % | 9.29 | |||||
| ROC (Joel Greenblatt) % | 13 | |||||
| ROCE % | 9.97 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21.84 | |||||
| PE Ratio without NRI | 10.06 | |||||
| Shiller PE Ratio | 28.36 | |||||
| PEG Ratio | 0.66 | |||||
| PS Ratio | 4.25 | |||||
| PB Ratio | 1.93 | |||||
| Price-to-Tangible-Book | 2.27 | |||||
| Price-to-Free-Cash-Flow | 18.22 | |||||
| Price-to-Operating-Cash-Flow | 12.36 | |||||
| EV-to-EBIT | 21.66 | |||||
| EV-to-EBITDA | 16.8 | |||||
| EV-to-Revenue | 4.55 | |||||
| EV-to-FCF | 20.71 | |||||
| Price-to-Projected-FCF | 1.31 | |||||
| Price-to-Median-PS-Value | 2.37 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.81 | |||||
| Price-to-Graham-Number | 0.93 | |||||
| Earnings Yield (Greenblatt) % | 4.62 | |||||
| FCF Yield % | 5.17 | |||||
| Forward Rate of Return (Yacktman) % | 17.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Replek AD Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MKD) | 1,006.344 | ||
| EPS (TTM) (MKD) | 755.424 | ||
| Beta | 0 | ||
| Volatility % | 28.26 | ||
| 14-Day RSI | 77.05 | ||
| 14-Day ATR (MKD) | 212.286252 | ||
| 20-Day SMA (MKD) | 15530.7 | ||
| 12-1 Month Momentum % | 61.27 | ||
| 52-Week Range (MKD) | 9300 - 18998 | ||
| Shares Outstanding (Mil) | 0.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Replek AD Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Replek AD Stock Events
| Event | Date | Price(MKD) | ||
|---|---|---|---|---|
| No Event Data | ||||
Replek AD Frequently Asked Questions
What is Replek AD(XMAE:REPL)'s stock price today?
The current price of XMAE:REPL is MKD16500.00. The 52 week high of XMAE:REPL is MKD18998.00 and 52 week low is MKD9300.00.
When is next earnings date of Replek AD(XMAE:REPL)?
The next earnings date of Replek AD(XMAE:REPL) is .
Does Replek AD(XMAE:REPL) pay dividends? If so, how much?
The Dividend Yield %  of Replek AD(XMAE:REPL) is 1.82% (As of Today), Highest Dividend Payout Ratio of Replek AD(XMAE:REPL) was 0.87. The lowest was 0.09. And the median was 0.61. The  Forward Dividend Yield % of Replek AD(XMAE:REPL) is 1.82%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers